Results 41 to 50 of about 70,439 (302)

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease

open access: yesTherapeutic Advances in Chronic Disease, 2019
Background: Inhaled levodopa may quickly resolve off periods in Parkinson’s disease. Our aim was to determine the pharmacokinetics and tolerability of a new levodopa dry-powder inhaler.
Marianne Luinstra   +9 more
doaj   +1 more source

Effects of levodopa on gut bacterial antibiotic resistance in Parkinson’s disease rat

open access: yesFrontiers in Aging Neuroscience, 2023
The second most prevalent neurodegenerative ailment, Parkinson’s disease (PD), is characterized by both motor and non-motor symptoms. Levodopa is the backbone of treatment for PD at the moment.
Shuo Sheng   +6 more
doaj   +1 more source

Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. [PDF]

open access: yes, 2015
In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited.
Alessandro eStefani   +9 more
core   +3 more sources

Impact of initial treatment on future symptoms and quality of life in Parkinson's disease

open access: yesChinese Journal of Contemporary Neurology and Neurosurgery, 2022
Objective To explore the effects of different initial drug treatment on motor symptoms, cognitive function and quality of life in patients with Parkinson's disease (PD).
LI Yu⁃wang   +5 more
doaj   +1 more source

Criteria for the diagnosis of corticobasal degeneration [PDF]

open access: yes, 2013
Current criteria for the clinical diagnosis of pathologically confirmed corticobasal degeneration (CBD) no longer reflect the expanding understanding of this disease and its clinicopathologic correlations.
Armstrong, Melissa J   +19 more
core   +1 more source

Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi   +19 more
wiley   +1 more source

Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia

open access: yesNeurobiology of Disease, 2016
Ras homolog enriched in striatum (Rhes) is a small GTP-binding protein that modulates signal transduction at dopamine receptors, and also activates mammalian target of rapamycin complex 1 (mTORC1). Rhes binding to mTORC1 is hypothesized to play a role in
Alberto Brugnoli   +3 more
doaj   +1 more source

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease [PDF]

open access: yes, 2003
Background: Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown. Methods: We conducted a five-
Krack, P.   +11 more
core   +4 more sources

Validity of a Wearable Digital Insole for Assessing Gait ON and OFF in Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Gait impairment is a distinctive symptom of Parkinson's disease that negatively impact mobility. We assessed the validity of wearable digital insoles against a validated reference gait analysis system for measuring select gait characteristics in patients with Parkinson's disease. Methods A comparative analysis between digital insoles
Deborah A. Hall   +16 more
wiley   +1 more source

Prescribing patterns and determinants for elderly patients with Parkinson's disease in Japan: a retrospective observational study using insurance claims databases

open access: yesFrontiers in Neurology, 2023
BackgroundThis study aimed to determine real-world prescribing patterns and determinants for Japanese patients with Parkinson's disease (PD), with a focus on patients ≥75 years.MethodsThis was a retrospective, observational, longitudinal study of ...
Morinobu Seki   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy